Asked by: Charles Walker (Conservative - Broxbourne)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what is the total per patient cost to the NHS from commissioning to delivery of administering via injection two doses of the covid-19 vaccine ; and if he will make a statement.
Answered by Maggie Throup
As of October 2021, the National Audit Office estimates that the total average deployment cost of two doses of the COVID-19 vaccine for the National Health Service is £51.40 in England.
Asked by: Charles Walker (Conservative - Broxbourne)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether his Department plans to allocate funding to support research into next generation covid-19 vaccinations that can be administered orally and nasally; and if he will make statement.
Answered by Maggie Throup
The Department commissions research through the National Institute for Health Research (NIHR). The NIHR and UK Research and Innovation have co-funded research on oral and nasal ingestion of the COVID-19 vaccine. Approximately £580,000 was awarded to Imperial College London for a study on two candidate vaccines administered to the respiratory tract. The NIHR is also providing infrastructure support to two phase one studies in this area through the University of Oxford and Imperial College London. The NIHR welcomes funding applications for research into any aspect of human health, including alternative vaccine delivery methods.
Asked by: Charles Walker (Conservative - Broxbourne)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what guidance he has issued to NHS hospital, community and mental health trusts on (a) recognising and (b) managing the risk that prescribed insulin poses to patients with a dual diagnosis of Type 1 Diabetes and an eating disorder; and if he will make a statement.
Answered by Gillian Keegan - Secretary of State for Education
NHS England and NHS Improvement’s ‘Adult Eating Disorders: Community, Inpatient and Intensive Day Patient Care – Guidance for commissioners and providers’, published in August 2019, guidance on managing comorbid conditions including diabetes. NHS England and NHS Improvement have developed two pilot services to test, trial and evaluate the effects of integrated diabetes and mental health pathways for the identification, assessment and treatment of patients with type 1 diabetes and disordered eating in London and the South. The draft evaluation for the pilots found that a means of increasing awareness among healthcare professionals of the risks for those who have type 1 diabetes and an eating disorder, should be developed to aid identification and diagnosis.
Asked by: Charles Walker (Conservative - Broxbourne)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, when he plans to answer Question 79292, tabled by the hon. Member for Broxbourne on 22 November 2021, regarding coronavirus and vaccination.
Answered by Edward Argar - Minister of State (Ministry of Justice)
I refer the hon. Member to the answer to Question 79292.
Asked by: Charles Walker (Conservative - Broxbourne)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, when he expects the MHRA to license a covid-19 nasal vaccine; and whether approval of nasal vaccines will be fast-tracked in line with injectable covid-19 vaccines; and if he will make a statement.
Answered by Maria Caulfield - Parliamentary Under Secretary of State (Department for Business and Trade) (Minister for Women)
Any route to approval of nasal vaccine treatments is subject to the developer seeking regulatory approval from the Medicines and Healthcare products Regulatory Agency (MHRA). The MHRA is therefore unable to provide a timetable for the approval of a COVID-19 nasal vaccine, as information on products not approved for use in the United Kingdom is commercially and market-sensitive. As with all other COVID-19 vaccines, the MHRA will ensure a thorough and expedited assessment of any such medicine’s safety and efficacy before any authorisation.
Asked by: Charles Walker (Conservative - Broxbourne)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if the Government will make an assessment of the potential merits of providing financial compensation to UK citizens who were required to quarantine in hotels for the period starting at 4:00am on 28 November 2021; and if he will make a statement.
Answered by Maggie Throup
We have no plans to make this assessment. There are no refunds or financial compensation available for guests who completed their quarantine period and had checked out of the managed quarantine hotel on or before 4am on 15 December. From 4pm on 15 December, guests with a negative polymerase chain reaction (PCR) test result and those who had not yet taken a PCR test were able to depart the quarantine hotel. In England, guests who were released early from managed quarantine are entitled to a refund for the unused part of their stay.